This means that immunohistochemical analyses linking ESRP1 and ESRP2 expression with more aggressive disease progression might also be useful as prostate cancer biomarkers to apply in parallel to Gleason grading [28]. The gene discussed is ESRP1; the disease is prostate cancer.